Skip to main content

Table 2 Patient demographics and baseline characteristics at study entry (parent study safety population)

From: Long-term safety and tolerability of bapineuzumab in patients with Alzheimer’s disease in two phase 3 extension studies

  3001 ApoE ε4 carrier study 3000 ApoE ε4 noncarrier study
  PBO (n = 215) BAP 0.5 (n = 275) PBO (n = 76) BAP 0.5 (n = 66) BAP 1.0 (n = 56)
Mean age (years) 69.8 70.6 67.3 69.8 68.9
Femalea (%) 62.3 67.6 61.8 53.0 62.5
Whitea (%) 80.9 75.3 78.9 74.2 66.1
Asian (%) 18.1 22.9 21.1 25.8 32.1
Mean duration of AD (years) 2.89 2.98 2.73 2.85 2.87
Mean baseline MMSE 21.3 21.4 20.2 20.8 20.6
Current AChEI and/or memantine use, n (%)
 Yes 199 (92.6) 255 (92.7) 70 (92.1) 56 (84.8) 54 (96.4)
 No 16 (7.4) 20 (7.3) 6 (7.9) 10 (15.2) 2 (3.6)
ApoE ε4 allele count, n (%)
 1 171 (79.5) 217 (78.9) NA NA NA
 2 44 (20.5) 58 (21.1) NA NA NA
  1. AChEI acetylcholinesterase inhibitor, AD Alzheimer’s disease, ApoE apolipoprotein E, BAP bapineuzumab, MMSE Mini-Mental State Examination, NA not applicable, PBO placebo
  2. aA few patients may have been misclassified at baseline, causing discrepancy with Table 3: one patient was classified as male at parent baseline and female at extension baseline; three patients were classified as white at parent baseline and Asian or “other” at extension baseline